Breaking News

Merck To Acquire Avecia Biologics

Merck buys bio-CMO, will focus on internal pipeline.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck will acquire Avecia Biologics from the Avecia group through its affiliate Merck Sharp & Dohme. Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed. “At Merck we continue to execute on our strategy of expanding our biopharmaceutical expertise and manufacturing capacity,” said John T. McCubbins, senior vice president, Biologics and Therapeutic Protein Opera...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters